检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:孙岩[1] SUN Yan(Jiamusi Central Hospital,Heilongjiang Province,Jiamusi 154002,China)
机构地区:[1]黑龙江省佳木斯市中心医院,黑龙江佳木斯154002
出 处:《中国医学创新》2022年第12期116-119,共4页Medical Innovation of China
摘 要:目的:研究多西他赛联合卡铂及曲妥珠单抗新辅助化疗对Ⅰ、Ⅱ期HER2阳性乳腺癌患者的疗效及生存预后的影响。方法:选取2017年1月-2019年1月佳木斯市中心医院收治的113例患者,按照随机数字表法将其分为研究组(n=56)及对照组(n=56)。对照组实施多西他赛联合卡铂新辅助化疗,研究组则在对照组的基础上增用曲妥珠单抗。比较两组疗效、HER2阴性表达情况、毒副反应发生情况、血清肿瘤相关炎症指标[白细胞介素-6(IL-6)、白细胞介素-8(IL-8)及白细胞介素-1β(IL-1β)]。结果:研究组总有效率及疾病控制率均高于对照组,差异均有统计学意义(P<0.05)。化疗后,研究组HER2阴性表达率高于对照组,而HER2强阳性表达率低于对照组,差异均有统计学意义(P<0.05)。两组恶心呕吐、骨髓抑制、心脏毒性、肝功能损害发生率比较,差异均无统计学意义(P>0.05)。化疗后,研究组血清IL-6、IL-8及IL-1β水平均低于对照组,差异均有统计学意义(P<0.05)。结论:Ⅰ~Ⅱ期HER2阳性乳腺癌患者经多西他赛联合卡铂及曲妥珠单抗新辅助化疗的疗效显著,可下调血清肿瘤相关炎症因子水平。Objective:To study the effect and survival prognosis of neoadjuvant chemotherapy with Docetaxel combined with Carboplatin and Trastuzumab in patients with stage Ⅰ,Ⅱ HER2-positive breast cancer.Method:A total of 113 patients admitted to the Jiamusi Central Hospital from January 2017 to January 2019 were selected,they were randomly divided into study group (n=56) and control group (n=56) according to random number table method.The control group received Docetaxel combined with Carboplatin neoadjuvant chemotherapy,while the study group received Trastuzumab on the basis of the control group.Efficacy,HER2 negative expression,incidence of toxic and side reactions,and serum tumor-related inflammation indicators[interleukin-6 (IL-6),interleukin-8 (IL-8) and interleukin-1 β (IL-1β)]were compared between two groups.Result:The total effective rate and disease control rate in the study group were higher than those in the control group,the differences were statistically significant (P<0.05).After chemotherapy,the negative HER2 expression rate in the study group was higher than that in the control group,while the strong HER2 positive expression rate was lower than that in the control group,the differences were statistically significant (P<0.05).There were no significant differences in the incidence of nausea and vomiting,bone marrow suppression,cardiotoxicity and liver function damage between two groups (P>0.05).After chemotherapy,the levels of serum IL-6,IL-8 and IL-1β in the study group were lower than those in the control group,the differences were statistically significant (P<0.05).Conclusion:Neoadjuvant chemotherapy with Docetaxel combined with Carboplatin and Trastuzumab has significant efficacy in patients with stage Ⅰ,Ⅱ HER2-positive breast cancer,which can effectively down-regulate the levels of tumor associated inflammatory factors.
关 键 词:乳腺癌 人表皮生长因子受体2 多西他赛 卡铂 曲妥珠单抗
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.33